Please provide your email address to receive an email when new articles are posted on . Neoadjuvant immunotherapy may help expand access to surgical resection for hepatocellular carcinoma. More ...

UAB General Surgery resident Tejeshwar Jain, M.D., received the 2025 Residents Research Award from the Society for Surgery of the Alimentary Tract for his project named “Evaluating a novel TLR4-based ...

Hepatocellular carcinoma (HCC) is a major global health issue, with significant morbidity and mortality rates. As the sixth most common cancer and the third leading cause of cancer-related deaths, HCC ...

Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial The trials were conducted ...

FAYETTEVILLE, GA, UNITED STATES, January 26, 2026 /EINPresswire.com/ -- Postoperative recurrence remains the main ...

Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide, largely due to its high rate of ...

Immune checkpoint inhibitor (ICI) therapy before surgery for hepatocellular carcinoma (HCC) may produce major pathological response in about one-third of the surgical patients. The clinical and ...

Background and Aim Surgery is the standard treatment option for hepatocellular carcinoma (HCC) meeting the Milan criteria, defined as single HCC ≤ 5 cm in maximum diameter or up to three nodules ≤ 3 ...

Robert Cannon, M.D., the surgical director of the UAB Liver Transplant Program, was recently featured on UAB's MedCast Podcast. In the episode, Cannon discusses the diagnosis and treatment options ...